Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00451724 · ClinicalTrials.gov registry record · Phase 2
Intranasal Ketamine for Procedural Sedation in Pediatric Laceration Repair
A Phase 2 study of Laceration, sponsored by Rhode Island Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
- 1
- Study location
NCT00451724: Completed Phase 2 study of Laceration, sponsored by Rhode Island Hospital.
NCT00451724 is a Phase 2 study of Laceration that has completed, run by Rhode Island Hospital. The registered enrollment target is 45 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (66% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00451724, a Phase 2 study of Laceration, has completed, sponsored by Rhode Island Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to compare how well three different doses of ketamine, given as a spray into the nose, help to sedate children and help them tolerate repairs of cuts on their faces.
Conditions Studied
Interventions
- DRUG Intranasal ketamine
Study Locations (1)
Rhode Island
- Hasbro Children's Hospital - Providence
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2007-05 |
| Est. Completion | 2010-02 |
| Phase | Phase 2 |
What the finished NCT00451724 record still lists
NCT00451724 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (66% lower).
The record links to 1 condition, with Laceration appearing as the primary indexed condition, and to 1 intervention - of which Intranasal ketamine is the first listed.
NCT00451724 reports a single indexed study location in Rhode Island.
Frequently Asked Questions
What is clinical trial NCT00451724 about?
NCT00451724 is a clinical study titled "Intranasal Ketamine for Procedural Sedation in Pediatric Laceration Repair". The purpose of this study is to compare how well three different doses of ketamine, given as a spray into the nose, help to sedate children and help them tolerate repairs of cuts on their faces.
What is the current status of trial NCT00451724?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2007-05. Estimated completion is 2010-02.
What conditions does trial NCT00451724 study?
This clinical trial studies the following conditions: Laceration.
What interventions are being tested in trial NCT00451724?
The interventions under investigation include: Intranasal ketamine (DRUG).
Who is sponsoring clinical trial NCT00451724?
This trial is sponsored by Rhode Island Hospital, which has 130 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00451724 being conducted?
This trial has 1 study location across Rhode Island. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00451724's enrollment target sits among peer trials
45 1296th of 2000 higher than 679 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia